Literature DB >> 11575860

Malignant struma ovarii: an unusual presentation.

A Checrallah1, R Medlej, C Saadé, G Khayat, G Halaby.   

Abstract

Malignant struma ovarii is a rare disease; only a few cases are well documented in the literature. Thus, the overall prognosis and modalities of treatment are still somewhat controversial. In this article, the authors report a case of malignant struma ovarii discovered 4 years after ovariectomy after metastasis to the lungs and bones. Review of the pathology of the ovarian struma did not reveal the classic criteria of malignancy, there were, however, many features considered to be atypical and thus suspicious. The patient was treated by total thyroidectomy followed by repetitive doses of 131I. However, because of difficulties in increasing the level of endogenous thyrotropin (TSH) because of functional thyroid metastases in such an advanced disease, recombinant human thyrotropin (rhTSH; Thyrogen, thyrotropin alpha, Genzyme Corporation, Cambridge, MA) was used before administration of radioiodine. With this therapeutic protocol, the patient is still clinically stable 2 years after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11575860     DOI: 10.1089/105072501316973163

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

Review 1.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

2.  Usefulness of (131)I-SPECT/CT and (18)F-FDG PET/CT in Evaluating Successful (131)I and Retinoic Acid Combined Therapy in a Patient with Metastatic Struma Ovarii.

Authors:  Hyo Jung Seo; Young Hoon Ryu; Inki Lee; Hye Sook Min; Keon Wook Kang; Dong Soo Lee; Dae-Hee Lee; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2014-09-25

3.  Malignant struma ovarii: a case report and review of the literature.

Authors:  M L Mattucci; A Dellera; A Guerriero; F Barbieri; L Minnelli; L Furlani
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

4.  Malignant Struma Ovarii Τreated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Miklos Acs; Sebastian Häusler; Hamid-Reza Lighvani; Jozef Zustin; Pompiliu Piso
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

5.  Struma ovarii with papillary thyroid carcinoma.

Authors:  Daniel M Alvarez; Victor Lee; Shweta Bhatt; Vikram S Dogra
Journal:  J Clin Imaging Sci       Date:  2011-08-27

6.  Extensive peritoneal implant metastases of malignant struma ovarii treated by thyroidectomy and 131I therapy: A case report.

Authors:  Mengxue Wu; Fengqiong Hu; Xing Huang; Zuwen Tan; Chengming Lei; Dong Duan
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

7.  Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.

Authors:  Sijian Li; Tengyu Yang; Yang Xiang; Xiaoyan Li; Limeng Zhang; Shan Deng
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

8.  Survival Outcomes and Prognostic Predictors in Patients With Malignant Struma Ovarii.

Authors:  Sijian Li; Shujun Kong; Xiaoxue Wang; Xinyue Zhang; Min Yin; Jiaxin Yang
Journal:  Front Med (Lausanne)       Date:  2021-12-23

9.  Malignant struma ovarii with thyroid-type papillary and poorly differentiated carcinoma: a case report.

Authors:  Nao Terayama; Satoe Fujiwara; Shoko Ueda; Takashi Yamada; Masahide Ohmichi
Journal:  J Med Case Rep       Date:  2022-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.